Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 1/20 | 0.41 |
| ▸ | RXRB | P28702 | 1/20 | 0.41 |
| ▸ | RXRG | P48443 | 1/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 7/20 | 0.40 |
| ▸ | RORC | P51449 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
| ▸ | MMP8 | P22894 | 4/20 | 0.37 |
| ▸ | MMP3 | P08254 | 2/20 | 0.37 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.37 |
| ▸ | PTGDR | Q13258 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4840814 | 0.95 | MAPT (0.38) | PTGDR2RORCMAPTTRPA1MMP8 | |
| SCHEMBL4840063 | 0.92 | RXRA (0.40) | RXRARXRBRXRGRORCMMP8 | |
| SCHEMBL4845014 | 0.91 | FFAR4 (0.42) | RXRARXRBRXRGRORCTRPA1 | |
| SCHEMBL4841606 | 0.91 | FFAR4 (0.43) | RXRARXRBRXRGRORCMMP8 | |
| SCHEMBL4845420 | 0.91 | FFAR4 (0.43) | RXRARXRBRXRGRORCMMP8 | |
| SCHEMBL4834080 | 0.91 | POLB (0.41) | PTGDR2MAPTMMP8MMP3 | |
| SCHEMBL4840055 | 0.90 | MMP8 (0.42) | MAPTMMP8MMP3 | |
| SCHEMBL4833071 | 0.89 | PTGDR2 (0.40) | RXRARXRBRXRGPTGDR2MMP8 | |
| SCHEMBL4845303 | 0.88 | MAPT (0.42) | PTGDR2MAPTTRPA1MMP8MMP3 | |
| SCHEMBL4837344 | 0.88 | RORC (0.43) | RORCMMP8MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7465811-B2 | Indoline compounds | LABORATOIRES FOURNIER S.A. (FR) | 2008-12-16 | — | — | US | disclosed |
| US-20080119465-A1 | Novel Indoline Compounds | LABORATORIES FOURNIER S.A. (FR) | 2008-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119465-A1 | Novel Indoline Compounds | GPR119, INSR, IRS1 | RXRA 1572/4885RXRB 1554/4885RXRG 1526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.